(Q33706220)

28 July 2017

1 reference

title

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. (English)

1 reference

28 July 2017

1 reference

Gamelin E

1

1 reference

PubMed ID

10439055

28 July 2017

Boisdron-Celle M

series ordinal

2

1 reference

PubMed ID

10439055

28 July 2017

language of work or name

1 reference

1 March 1999

1 reference

Critical Reviews in Oncology Hematology

28 July 2017

1 reference

28 July 2017

30

1 reference

28 July 2017

71-79

1 reference

28 July 2017

1

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

28 July 2017

1 reference

7 January 2021

Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Fluorouracil: biochemistry and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Pharmacodynamics in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

DoseVersus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Metabolism and mechanism of action of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in patients with advanced colonic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Population study of dihydropyrimidine dehydrogenase in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Influence of sex and age on fluorouracil clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Elevated urine, blood and cerebrospinal fluid levels of uracil and thymine in a child with dihydrothymine dehydrogenase deficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Automated screening system for purine and pyrimidine metabolism disorders using high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

A Simple Chromatographic Method for the Analysis of Pyrimidines and their Dihydrogenated Metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Co-variables influencing 5-fluorouracil clearance during continuous venous infusion. A NONMEM analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2898%2900036-5

7 January 2021

10.1016/S1040-8428(98)00036-5

Identifiers

DOI

1 reference

28 July 2017

1 reference

PubMed ID

10439055